Analysis of mutations associated with Parkinson’s disease in patients of the Krasnoyarsk region

Background. Parkinson’s disease (PD) is one of the common neurodegenerative diseases. Several genes are known (SNCA, PARK2, PINK1, PARK7 (DJ-1) and LRRK2), mutations in which have a pathological significance in the development of monogenic PD; association with PD of other genes (for example, UCHL1, ATP13A2) requires further study. It is also known, that GBA gene is associated with an increased risk of PD developing.

Aim. Analysis of mutations and polymorphisms in the PARK2, PINK1, SNCA, ATP13A2, PARK7, LRRK2, UCHL, GCH1 and GBA genes in patients with PD from Krasnoyarsk region.

Material and methods. The 60 patients with sporadic and familial forms of PD were included in the study. The SALSA MLPA Holland P051 and P052 kits («MRC Amsterdam», The Netherlands) were used to detect deletions and duplications in the PARK2, PINK1, SNCA, ATP13A2, PARK7, LRRK2, UCHL, GCH1 genes, as well as point mutations A30P in the SNCA gene and G2019S in the LRRK2 gene. Analysis of the GBA gene was carried out by Senger sequencing.

Results. None of the 60 patients had mutations that were searched with the SALSA MLPA Holland P051 and P052 kits. 6 different mutations in the GBA gene were found in 9 out of 60 patients with PD. L444P («severe» PD — associated mutation) — in two patients, D409H («severe» PD — associated mutation) — in one patient, T369M (polymorphism, possibly associated with PD) — in two patients, E326K (polymorphism, possibly associated with PD) — in one patient, V460V (synonymous variant, which is part of the composition of the complex RecNcil mutation (p.L444P; p.A456P; p.V460V) associated with PD) — in two patients and variant C.*92g>A (3’ — UTR polymorphism, possibly associated with PD) — in one patient. Two patients had compound heterozygous carriers of two variants.

Conclusion. This paper presents the genetic analysis results of the PD associated genes among patients from the Krasnoyarsk region. No mutations were detected in the PARK2, PINK1, SNCA, ATP13A2, PARK7, LRRK2, UCHL and GCH1 genes. Genetic variants analysis of the GBA gene showed similar frequency in the patients from the Krasnoyarsk region as in European populations.

1. Levin O.S., Fedorova N.V. Parkinson’s disease. M., MEDpress-inform, 2012:351. (In Russ.). https://elibrary.ru/item.asp?id=19562937

2. Pchelina S.N., Emelyanov A.K., Usenko T.S. Molecular basis of Parkinsons’s disease linked to LRRK2 mutations. Molecular biology. 2014;48(1):1–10. (in Russ.). https://elibrary.ru/download/elibrary_21141356_68298623.pdf

3. Gasser T. Update on the Genetics of Parkinson’s Disease. Mov. Disord. 2007;22:343–350. https://doi.org/10.1002/mds.21676

4. Klein C., Lohmann-Hedrich K., Rogaeva E., Schlossmacher G.M., Lang E A. Deciphering the role of heterozygous mutations in genes associated with parkinsonism. Lancet Neurol. 2007;6:652–62. https://doi.org/10.1016/S1474-4422(07)70174-6

5. Singleton A.B., Farrer M.J., Bonifati V. The genetics of Parkinson’s disease: progress and therapeutic implications. Mov. Disord. 2013;28:14–23. https://doi.org/10.1002/mds.25249

6. Illarioshkin S.N., Periquet M., Rawal N. Mutation analysis of the parkin gene in Russian families with autosomal recessive juvenile Parkinsonism. Mov. Disord. 2003;18(8):914–919. https://doi.org/10.1002/mds.10467

7. Guo J.-F., Dong X.-L., Xu Q., Li N., Yan X.-X., Xia K. et al. Exon dosage analysis of parkin gene in Chinese sporadic Parkinson’s disease. Neuroscience Letters. 2015;604:47–51. https://doi.org/10.1016/j.neulet.2015.07.046

8. Elfferich P., Verleun-Mooijman M.C., Anneke Maat-Kievit J., van de Warrenburg B.P.C., Abdo W.F., Eshuis S.A. et al. Breakpoint mapping of 13 large parkin deletions/duplications reveals an exon 4 deletion and an exon 7 duplication as founder mutations. Neurogenetics. 2011;12(4):263–271. https://doi.org/10.1007/s10048-011-0302-9

9. Singleton A.B., Farrer M., Johnson J., Singleton A., Hague S., Kachergus J. Alpha-Synuclein locus triplication causes Parkinson’s disease. Science. 2003;302:841. https://doi.org/10.1126/science.1090278

10. Lesage S., Brice A. Parkinson’s disease: from monogenic forms to genetic susceptibility factors. Hum. Mol. Genet. 2009;18(1):48– 59. https://doi.org/10.1093/hmg/ddp012

11. Illarioshkin S.N., Slominskiy P.A., Shadrina M.I. Heterogeneity of sporadic Parkinson’s disease: molecular approach to solving the problem. Annals of Clinical and Experimental Neurology. 2007;1(1):23–31. (in Russ.).

12. Vitte J., Traver S., Maués De Paula A., Lesage S., Rovelli G., Corti O. et al. Leucinerich repeat kinase 2 is associated with the endoplasmic reticulum in dopaminergic neurons and accumulates in the core of Lewy bodies in Parkinson disease. J. Neuropathol. Exp. Neurol. 2010;69(9):959–972. https://doi.org/10.1097/NEN.0b013e3181efc01c

13. Berg D., Schweitzer K.J., Leitner P., Zimprich A., Lichtner P., Belcredi P. et al. Type and frequency of mutations in the LRRK2 gene in familial and sporadic Parkinson’s disease. Brain. 2005;128:3000–3011. https://doi.org/10.1093/brain/awh666

14. Paisan-Ruiz C., Lang A.E., Kawarai T., Sato C., SalehiRad S., Fisman G.K. et al. LRRK2 gene in Parkinson disease: mutation analysis and case control association study. Neurology. 2005;65:696–700. https://doi.org/10.1212/01.WNL.0000167552.79769.b3

15. Illarioshkin S.N., Shadrina M.I., Slominsky P.A. A common leucine-rich repeat kinase 2 gene mutation in familial and sporadic Parkinson’s disease in Russia. European Journal of Neurology. 2007;14:413–417. https://doi.org/10.1111/j.1468-1331.2006.01685.x

16. Tan E.-K., Yew K., Chua E., Puvan K., Shen H., Lee E. et al. PINK1 mutations in sporadic earlyonset Parkinson’s disease. Mov. Disord. 2006;21:789–93. https://doi.org/10.1002/mds.20810

17. Hedrich K., Djarmati A., Schafer N., Hering R., Wellenbrock C., Weiss P.H. et al. DJ-1 (PARK7) mutations are less frequent than Parkin (PARK2) mutations in early-onset Parkinson disease. Neurology. 2004;62:389–394. https://doi.org/10.1212/01.WNL.0000113022.51739.88

18. Filatova E.V., Alieva A.H., Shadrina M.I. Analysis of Mutations in Patients with Suspected Autosomal Dominant Form of the Parkinson Disease. Molecular Genetics, Microbiology and Virology. 2014;1:3–4. (in Russ.).

19. Saigoh K., Wang Y.-L., Suh J.-G., Yamanishi T., Sakai Y., Kiyosawa H. et al. Intragenic deletion in the gene encoding ubiquitin carboxy-terminal hydrolase in gad mice. Nat. Genet. 1999;23(1):47–51. https://doi.org/10.1038/12647

20. Mencacci N., Isaias I., Reich M., Ganos C., Polke J., Bras J. et al. Mutations in the GCH1 Gene Are Associated with Parkinson Disease. Neurology. 2014;82(10):17–23. https://n.neurology.org/content/82/10_Supplement/S17.001

21. Illarioshkin S.N., Levin O.S. Parkinson’s disease and movement disorders. Мoskva: ZAO «RKI Sovero press», 2014:405. (In Russ.). http://www.parkinsonizm.ru/?page=148

22. Illarioshkin S.N., Levin O.S. Parkinson’s disease and movement disorders. Мoskva, 2017:381 p. (In Russ.). http://www.parkinsonizm.ru/?page=171

23. Gankina O.A., Vasenina E.E., Levin O.S. Characteristics of Parkinson’s disease course in the heterozygous carriage of mutations in the glucocerebrosidase A gene. S.S. Korsakov Journal of Neurology and Psychiatry. 2016;6(2):71–76. (in Russ.). https://doi.org/10.17116/jnevro20161166271-76

24. Abramycheva N.Y., Fedotova E.Y., Bagyeva G.K., Klyushnikov S.A., Ivanova-Smolenskaya I.A., Illarioshkin S.N. Mutations in the GBA gene in Parkinson’s disease. Medical Genetics. 2011;10(5):22–27. (in Russ.). https://elibrary.ru/item.asp?id=23026341

25. Darvish H., Movafagh A., Omrani M.D., Firouzabadi S.G., Azargashb E., Jamshidi J. et al. B. Detection of copy number changes in genes associated with Parkinson’s disease in Iranian patients. Neuroscience Letters. 2013;551:75–78. https://doi.org/10.1016/j.neulet.2013.07.013

26. Abramycheva N.Y., Fedotova E.Y., Stepanova M.S. New approach to molecular and genetic screening of patients with Parkinson’s disease. Neurological journal. 2016;1:13–16. (in Russ.). https://doi.org/10.18821/1560-9545-2016-21-1-13-16

27. Wilke M.V.M.B., Dornelles A.D., Schuh A.S., Vairo F.P., Basgalupp S.P., Siebert M. et al. Evaluation of the frequency of non-motor symptoms of Parkinson’s disease in adult patients with Gaucher disease type 1. Orphanet J Rare Dis. 2019;14:103. https://doi.org/10.1186/s13023-019-1079-4

28. Leroy E., Boyer R., Auburger G. The ubiquitin pathway in Parkinson’s disease. Nature. 1998;395:451–452. https://doi.org/10.1038/26652

29. Clark L.N., Ross B.M., Wang Y., MejiaSantana H., Harris J., Louis E.D. et al. Mutations in the glucocerebrosidase gene are associated with early-onset Parkinson disease. Neurology. 2007;69:1270–1277. https://doi.org/10.1212/01.wnl.0000276989.17578.02

30. Mata I.F., Ali Samii, Schneer S.H. Roberts J.W., Griffith A., Leis B.C. et al. Glucocerebrosidase gene mutations: A risk factor for Lewy body disorders. Arch. Neurol. 2008;65:379–382. https://doi.org/10.1001/archneurol.2007.68

31. Mitsui J., Mizuta I., Toyoda A., Ashida R., Takahashi Y., Goto J. et al. Mutations for Gaucher disease confer high susceptibility to Parkinson disease. Arch. Neurol. 2009;66:571–576. https://doi.org/10.1001/archneurol.2009.72